There have already been rare post-marketing reviews of cases of intestinal obstruction, and exacerbation of diverticulitis, several of which have expected clinical intervention to get rid of the tablet. Patients with underlying GI Ailments which include esophageal cancer or colon cancer with a small gastrointestinal lumen are at larger hazard of cr